"Oxidopamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
Concept/Terms
Oxidopamine- Oxidopamine
- 6-OHDA
- 6-Hydroxydopamine
- 6 Hydroxydopamine
Below are MeSH descriptors whose meaning is more general than "Oxidopamine".
Below are MeSH descriptors whose meaning is more specific than "Oxidopamine".
This graph shows the total number of publications written about "Oxidopamine" by people in Harvard Catalyst Profiles by year, and whether "Oxidopamine" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 2 | 2 |
| 1994 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 2 | 3 | 5 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 5 | 5 |
| 2001 | 2 | 4 | 6 |
| 2002 | 1 | 8 | 9 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 3 | 4 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 5 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 3 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 6 | 6 |
| 2015 | 0 | 4 | 4 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
Below are the most recent publications written about "Oxidopamine" by people in Profiles.
-
Early Repetitive Transcranial Magnetic Stimulation Exerts Neuroprotective Effects and Improves Motor Functions in Hemiparkinsonian Rats. Neural Plast. 2021; 2021:1763533.
-
Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease. Neurobiol Dis. 2021 07; 155:105368.
-
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism. Mov Disord. 2021 04; 36(4):927-937.
-
Promotion of mitochondrial biogenesis via the regulation of PARIS and PGC-1a by parkin as a mechanism of neuroprotection by carnosic acid. Phytomedicine. 2021 Jan; 80:153369.
-
Early transcranial direct current stimulation treatment exerts neuroprotective effects on 6-OHDA-induced Parkinsonism in rats. Brain Stimul. 2020 May - Jun; 13(3):655-663.
-
Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease. Exp Neurol. 2018 05; 303:95-107.
-
Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease. Neurobiol Dis. 2018 04; 112:136-148.
-
Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia. Neurobiol Aging. 2018 01; 61:82-92.
-
Absence of regulator of G-protein signaling 4 does not protect against dopamine neuron dysfunction and injury in the mouse 6-hydroxydopamine lesion model of Parkinson's disease. Neurobiol Aging. 2017 10; 58:30-33.
-
Cell-specific pallidal intervention induces long-lasting motor recovery in dopamine-depleted mice. Nat Neurosci. 2017 Jun; 20(6):815-823.